PVT-401
/ Parvus Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 08, 2025
Resilience Partners with Parvus Therapeutics for Development and Manufacturing of PVT401, a Novel Autoimmune Drug Candidate for IBD
(Businesswire)
- "National Resilience, Inc...today announced the expansion of its collaboration with Parvus Therapeutics ('Parvus') to support the development and manufacturing their second novel autoimmune drug candidate, PVT401, targeting Inflammatory Bowel Disease (IBD)."
Licensing / partnership • Inflammatory Bowel Disease
1 to 1
Of
1
Go to page
1